Latest Breaking News On - Drug designation - Page 7 : comparemela.com

Cyclo Therapeutics : Corporate Presentation

NASDAQ: CYTH cyclotherapeutics.com Forward-Looking Statements 2 .

United statesSouth africaBenny liuGeraldf coxSharonh hrynkowMichael lisjakKaren mullenCaroline hastingsRita colwellLori gorskiJeffreyl tateUniversity professorNational medal of scienceUniversity of the witwatersrandKantar healthTessellon inc

FDA Grants Orphan Drug Designation for CAN-2409 to Treat Pancreatic Cancer

The designation was granted based on overall survival data from an ongoing randomized phase 2 clinical trial.

Sebastian kaulitzkiGarrett nicholsNational cancer instituteNational library of medicineCandel therapeutics incOrphan drug designationCandel therapeuticsChief medical officerEnd resultsPaul peter takChief executive officerOrphan drugFast track designationTherapeutics receivesDrug designation

FDA Grants Orphan Drug Designation for the Treatment of Scleroderma

/PRNewswire/ BLR Bio, an emerging biotechnology company in Rosalind Franklin University s Helix 51 biomedical incubator, announced that the U.S. Food and.

Ronald kaplanDrug administrationCanadian institutes of health researchRosalind franklin university of medicineUniversity of saskatchewanNational scleroderma foundationOffice of marketingRosalind franklin universityOrphan drug designationDrug designationBruce riserCanadian institutesHealth researchFranklin university

Candel Therapeutics Receives FDA Orphan Drug Designation for CAN-2409 for the Treatment of Pancreatic Cancer

Candel Therapeutics Receives FDA Orphan Drug Designation for CAN-2409 for the Treatment of Pancreatic Cancer
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesGarrett nicholsAljanae reynoldsTheodore jenkinsNational cancer instituteCandel therapeutics incBusiness developmentCompany nasdaqExchange commissionDrug administrationOrphan drug designationPaul peter takChief executive officerOrphan drugFast track designationChief medical officer

ViGeneron Announces First Patient Dosed in Phase 1b Clinical Trial of VG901 for the Intravitreal Treatment of Retinitis Pigmentosa

VG901 is the first and only clinical-stage therapy designed to deliver a functional CNGA1 gene to retinal photoreceptor target cells in retinitis .

United statesVigeneron gmbKatarina stinglShaun brown juliaMc servicesOrphan drug designationGeneron gmbhHereditary retinal degenerationsRare eye diseasesPrincipal investigatorDrug designationRetinitis pigmentosa